Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.
You may also be interested in...
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
The Contrave "complete response" letter could mean research in the category is sidelined now that all three of the current obesity drug candidates have been rejected.
Merck Buys Into Orna's Circular RNA Platform With Emphasis On Vaccines
Orna is retaining full ownership of its "crown jewel," in situ CAR programs for cancer. CEO Tom Barnes talked to Scrip about the deal and Orna's business strategy.
Pfizer's Prevnar 20 Edges Closer To Infant Market, But Phase III Raises Some Questions
The pediatric market represents 70%-75% of the market for pneumococcal vaccines; Merck & Co.'s Vaxneuvance was already approved for infants earlier this year.